HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1

Failure to eradicate hematologic cancer stem cells (hCSCs) associated with resistance to tyrosine kinase inhibitors such as imatinib mesylate (IM) in chronic myeloid leukemia (CML) patients is a clinical challenge that highlights the need for discovering and developing therapeutic strategies that ta...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Experimental cell research 2018-09, Vol.370 (2), p.519-530
Hauptverfasser: Bamodu, Oluwaseun Adebayo, Kuo, Kuang-Tai, Yuan, Li-Ping, Cheng, Wei-Hong, Lee, Wei-Hwa, Ho, Yuan-Soon, Chao, Tsu-Yi, Yeh, Chi-Tai
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 530
container_issue 2
container_start_page 519
container_title Experimental cell research
container_volume 370
creator Bamodu, Oluwaseun Adebayo
Kuo, Kuang-Tai
Yuan, Li-Ping
Cheng, Wei-Hong
Lee, Wei-Hwa
Ho, Yuan-Soon
Chao, Tsu-Yi
Yeh, Chi-Tai
description Failure to eradicate hematologic cancer stem cells (hCSCs) associated with resistance to tyrosine kinase inhibitors such as imatinib mesylate (IM) in chronic myeloid leukemia (CML) patients is a clinical challenge that highlights the need for discovering and developing therapeutic strategies that target and eliminate these hCSCs. Herein, we document the essential role of the interplay between histone deacetylases (HDACs), the polycomb group proteins, pluripotency transcription factors and the cell cycle machinery in the viability, oncogenicity and therapy evasion of IM-resistant CD34+/CD38- CML stem cells (CML-SCs). Using the proteotranscriptomic analyses of wild type (WT), CD34+/CD38+ and CD34+/CD38− K562 or KU812 cells, we showed that CD34+/CD38− SC-enriched cells expressed significantly higher levels of CD44, CD133, SOX2, Nanog, OCT4, and c-Myc mRNA and/or protein, compared to the WT or CD34+/CD38+ cells. This overexpression of stemness factors in the CD34+/CD38− cells positively correlates with enhanced expression of HDACs 1–6, cyclins D1/D3, CDK 2, 4 and 6, while inversely correlating with p18, p21 and p27. Enhanced co-expression of MDR1, survivin, and Bcl-2 proteins, supposedly involved in IM-resistance and CML-SC survival, was detected in both CD34+/CD38− and CD34+/CD38+ cells. Importantly, we demonstrate that in synergism with IM, SAHA reverses the tumor-promoting proteotranscriptomic profile noted above and elicits marked inhibition of the CML-SCs by up-regulating hsa-miR-196a expression. This hsa-miR-196a-mediated SC-limiting effect of SAHA is dose-dependent, low-dosed, cell cycle-modulating and accompanied by leukemic SC apoptosis. Interestingly, this anti-SC therapeutic activity of SAHA in vitro was reproduced in vivo using the NOD-SCID mice models. [Display omitted] •hsa-miR-196a mediates inhibition of CML stem cells.•Potentiate the anticancer effect of Imatinib mesylate by suberanilohydroxamic acid.•Synergism with Imatinib mesylate and suberanilohydroxamic acid reverses the tumor-promoting proteotranscriptomic profile.
doi_str_mv 10.1016/j.yexcr.2018.07.017
format Article
fullrecord <record><control><sourceid>proquest_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_23082629</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014482718304403</els_id><sourcerecordid>2071579388</sourcerecordid><originalsourceid>FETCH-LOGICAL-c453t-fa38cd78172d1f883943a7908757d2fc2913d950381fdb5375d38cdabe52f6dc3</originalsourceid><addsrcrecordid>eNp9kc-O0zAQxi0EYkvhCZCQJS5ckvWfpHYOHLplYZEqIa3gbLn2JHVJ4mI7iL4Qz7kOWThymsP8vplv5kPoNSUlJXRzfSov8MuEkhEqSyJKQsUTtKKkIQWrGHuKVoTQqqgkE1foRYwnQoiUdPMcXfHcEQ2vVuj33YftDrvx6A4u-YDjdD4HiBEiPgffuxaCTs6PWI8Wp2nwwXUwOuPSBfsW2zB1ReZdTHpM2ByDz008XKD3zuIepu8wOI1jggEb6PuIU2am7ogDdFO_zM6DjlEXg7svaLPROOnQQXJjh29299fbmz19iZ61uo_w6rGu0bePt193d8X-y6fPu-2-MFXNU9FqLo0VkgpmaSslbyquRUOkqIVlrWEN5bapCZe0tYeai9rOAn2AmrUba_gavV3m-picivlMMEfjxxFMUowTyTasydS7hcov-jFBTGpwcb5Oj-CnqBgRtM7_zQbWiC-oCT7GAK06BzfocFGUqDlGdVJ_YlRzjIoIlZPJqjePC6bDAPaf5m9uGXi_AJCf8dNBmL3CaMC6MFu13v13wQOwVbGc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2071579388</pqid></control><display><type>article</type><title>HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1</title><source>Access via ScienceDirect (Elsevier)</source><creator>Bamodu, Oluwaseun Adebayo ; Kuo, Kuang-Tai ; Yuan, Li-Ping ; Cheng, Wei-Hong ; Lee, Wei-Hwa ; Ho, Yuan-Soon ; Chao, Tsu-Yi ; Yeh, Chi-Tai</creator><creatorcontrib>Bamodu, Oluwaseun Adebayo ; Kuo, Kuang-Tai ; Yuan, Li-Ping ; Cheng, Wei-Hong ; Lee, Wei-Hwa ; Ho, Yuan-Soon ; Chao, Tsu-Yi ; Yeh, Chi-Tai</creatorcontrib><description>Failure to eradicate hematologic cancer stem cells (hCSCs) associated with resistance to tyrosine kinase inhibitors such as imatinib mesylate (IM) in chronic myeloid leukemia (CML) patients is a clinical challenge that highlights the need for discovering and developing therapeutic strategies that target and eliminate these hCSCs. Herein, we document the essential role of the interplay between histone deacetylases (HDACs), the polycomb group proteins, pluripotency transcription factors and the cell cycle machinery in the viability, oncogenicity and therapy evasion of IM-resistant CD34+/CD38- CML stem cells (CML-SCs). Using the proteotranscriptomic analyses of wild type (WT), CD34+/CD38+ and CD34+/CD38− K562 or KU812 cells, we showed that CD34+/CD38− SC-enriched cells expressed significantly higher levels of CD44, CD133, SOX2, Nanog, OCT4, and c-Myc mRNA and/or protein, compared to the WT or CD34+/CD38+ cells. This overexpression of stemness factors in the CD34+/CD38− cells positively correlates with enhanced expression of HDACs 1–6, cyclins D1/D3, CDK 2, 4 and 6, while inversely correlating with p18, p21 and p27. Enhanced co-expression of MDR1, survivin, and Bcl-2 proteins, supposedly involved in IM-resistance and CML-SC survival, was detected in both CD34+/CD38− and CD34+/CD38+ cells. Importantly, we demonstrate that in synergism with IM, SAHA reverses the tumor-promoting proteotranscriptomic profile noted above and elicits marked inhibition of the CML-SCs by up-regulating hsa-miR-196a expression. This hsa-miR-196a-mediated SC-limiting effect of SAHA is dose-dependent, low-dosed, cell cycle-modulating and accompanied by leukemic SC apoptosis. Interestingly, this anti-SC therapeutic activity of SAHA in vitro was reproduced in vivo using the NOD-SCID mice models. [Display omitted] •hsa-miR-196a mediates inhibition of CML stem cells.•Potentiate the anticancer effect of Imatinib mesylate by suberanilohydroxamic acid.•Synergism with Imatinib mesylate and suberanilohydroxamic acid reverses the tumor-promoting proteotranscriptomic profile.</description><identifier>ISSN: 0014-4827</identifier><identifier>EISSN: 1090-2422</identifier><identifier>DOI: 10.1016/j.yexcr.2018.07.017</identifier><identifier>PMID: 30017934</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>60 APPLIED LIFE SCIENCES ; ALBUMINS ; BLOOD SERUM ; BORON CHLORIDES ; Chemoresistance ; Chronic myeloid leukemia ; HDAC inhibition ; Hematopoietic stem cells ; HISTONES ; hsa-miR-196a ; Imatinib ; MESSENGER-RNA ; MICE ; Myelogenous leukemia ; MYELOID LEUKEMIA ; PHOSPHOTRANSFERASES ; SAHA ; STEM CELLS ; TYROSINE</subject><ispartof>Experimental cell research, 2018-09, Vol.370 (2), p.519-530</ispartof><rights>2018 Elsevier Inc.</rights><rights>Copyright © 2018 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c453t-fa38cd78172d1f883943a7908757d2fc2913d950381fdb5375d38cdabe52f6dc3</citedby><cites>FETCH-LOGICAL-c453t-fa38cd78172d1f883943a7908757d2fc2913d950381fdb5375d38cdabe52f6dc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.yexcr.2018.07.017$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30017934$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/23082629$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Bamodu, Oluwaseun Adebayo</creatorcontrib><creatorcontrib>Kuo, Kuang-Tai</creatorcontrib><creatorcontrib>Yuan, Li-Ping</creatorcontrib><creatorcontrib>Cheng, Wei-Hong</creatorcontrib><creatorcontrib>Lee, Wei-Hwa</creatorcontrib><creatorcontrib>Ho, Yuan-Soon</creatorcontrib><creatorcontrib>Chao, Tsu-Yi</creatorcontrib><creatorcontrib>Yeh, Chi-Tai</creatorcontrib><title>HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1</title><title>Experimental cell research</title><addtitle>Exp Cell Res</addtitle><description>Failure to eradicate hematologic cancer stem cells (hCSCs) associated with resistance to tyrosine kinase inhibitors such as imatinib mesylate (IM) in chronic myeloid leukemia (CML) patients is a clinical challenge that highlights the need for discovering and developing therapeutic strategies that target and eliminate these hCSCs. Herein, we document the essential role of the interplay between histone deacetylases (HDACs), the polycomb group proteins, pluripotency transcription factors and the cell cycle machinery in the viability, oncogenicity and therapy evasion of IM-resistant CD34+/CD38- CML stem cells (CML-SCs). Using the proteotranscriptomic analyses of wild type (WT), CD34+/CD38+ and CD34+/CD38− K562 or KU812 cells, we showed that CD34+/CD38− SC-enriched cells expressed significantly higher levels of CD44, CD133, SOX2, Nanog, OCT4, and c-Myc mRNA and/or protein, compared to the WT or CD34+/CD38+ cells. This overexpression of stemness factors in the CD34+/CD38− cells positively correlates with enhanced expression of HDACs 1–6, cyclins D1/D3, CDK 2, 4 and 6, while inversely correlating with p18, p21 and p27. Enhanced co-expression of MDR1, survivin, and Bcl-2 proteins, supposedly involved in IM-resistance and CML-SC survival, was detected in both CD34+/CD38− and CD34+/CD38+ cells. Importantly, we demonstrate that in synergism with IM, SAHA reverses the tumor-promoting proteotranscriptomic profile noted above and elicits marked inhibition of the CML-SCs by up-regulating hsa-miR-196a expression. This hsa-miR-196a-mediated SC-limiting effect of SAHA is dose-dependent, low-dosed, cell cycle-modulating and accompanied by leukemic SC apoptosis. Interestingly, this anti-SC therapeutic activity of SAHA in vitro was reproduced in vivo using the NOD-SCID mice models. [Display omitted] •hsa-miR-196a mediates inhibition of CML stem cells.•Potentiate the anticancer effect of Imatinib mesylate by suberanilohydroxamic acid.•Synergism with Imatinib mesylate and suberanilohydroxamic acid reverses the tumor-promoting proteotranscriptomic profile.</description><subject>60 APPLIED LIFE SCIENCES</subject><subject>ALBUMINS</subject><subject>BLOOD SERUM</subject><subject>BORON CHLORIDES</subject><subject>Chemoresistance</subject><subject>Chronic myeloid leukemia</subject><subject>HDAC inhibition</subject><subject>Hematopoietic stem cells</subject><subject>HISTONES</subject><subject>hsa-miR-196a</subject><subject>Imatinib</subject><subject>MESSENGER-RNA</subject><subject>MICE</subject><subject>Myelogenous leukemia</subject><subject>MYELOID LEUKEMIA</subject><subject>PHOSPHOTRANSFERASES</subject><subject>SAHA</subject><subject>STEM CELLS</subject><subject>TYROSINE</subject><issn>0014-4827</issn><issn>1090-2422</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kc-O0zAQxi0EYkvhCZCQJS5ckvWfpHYOHLplYZEqIa3gbLn2JHVJ4mI7iL4Qz7kOWThymsP8vplv5kPoNSUlJXRzfSov8MuEkhEqSyJKQsUTtKKkIQWrGHuKVoTQqqgkE1foRYwnQoiUdPMcXfHcEQ2vVuj33YftDrvx6A4u-YDjdD4HiBEiPgffuxaCTs6PWI8Wp2nwwXUwOuPSBfsW2zB1ReZdTHpM2ByDz008XKD3zuIepu8wOI1jggEb6PuIU2am7ogDdFO_zM6DjlEXg7svaLPROOnQQXJjh29299fbmz19iZ61uo_w6rGu0bePt193d8X-y6fPu-2-MFXNU9FqLo0VkgpmaSslbyquRUOkqIVlrWEN5bapCZe0tYeai9rOAn2AmrUba_gavV3m-picivlMMEfjxxFMUowTyTasydS7hcov-jFBTGpwcb5Oj-CnqBgRtM7_zQbWiC-oCT7GAK06BzfocFGUqDlGdVJ_YlRzjIoIlZPJqjePC6bDAPaf5m9uGXi_AJCf8dNBmL3CaMC6MFu13v13wQOwVbGc</recordid><startdate>20180915</startdate><enddate>20180915</enddate><creator>Bamodu, Oluwaseun Adebayo</creator><creator>Kuo, Kuang-Tai</creator><creator>Yuan, Li-Ping</creator><creator>Cheng, Wei-Hong</creator><creator>Lee, Wei-Hwa</creator><creator>Ho, Yuan-Soon</creator><creator>Chao, Tsu-Yi</creator><creator>Yeh, Chi-Tai</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>OTOTI</scope></search><sort><creationdate>20180915</creationdate><title>HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1</title><author>Bamodu, Oluwaseun Adebayo ; Kuo, Kuang-Tai ; Yuan, Li-Ping ; Cheng, Wei-Hong ; Lee, Wei-Hwa ; Ho, Yuan-Soon ; Chao, Tsu-Yi ; Yeh, Chi-Tai</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c453t-fa38cd78172d1f883943a7908757d2fc2913d950381fdb5375d38cdabe52f6dc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>60 APPLIED LIFE SCIENCES</topic><topic>ALBUMINS</topic><topic>BLOOD SERUM</topic><topic>BORON CHLORIDES</topic><topic>Chemoresistance</topic><topic>Chronic myeloid leukemia</topic><topic>HDAC inhibition</topic><topic>Hematopoietic stem cells</topic><topic>HISTONES</topic><topic>hsa-miR-196a</topic><topic>Imatinib</topic><topic>MESSENGER-RNA</topic><topic>MICE</topic><topic>Myelogenous leukemia</topic><topic>MYELOID LEUKEMIA</topic><topic>PHOSPHOTRANSFERASES</topic><topic>SAHA</topic><topic>STEM CELLS</topic><topic>TYROSINE</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bamodu, Oluwaseun Adebayo</creatorcontrib><creatorcontrib>Kuo, Kuang-Tai</creatorcontrib><creatorcontrib>Yuan, Li-Ping</creatorcontrib><creatorcontrib>Cheng, Wei-Hong</creatorcontrib><creatorcontrib>Lee, Wei-Hwa</creatorcontrib><creatorcontrib>Ho, Yuan-Soon</creatorcontrib><creatorcontrib>Chao, Tsu-Yi</creatorcontrib><creatorcontrib>Yeh, Chi-Tai</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>OSTI.GOV</collection><jtitle>Experimental cell research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bamodu, Oluwaseun Adebayo</au><au>Kuo, Kuang-Tai</au><au>Yuan, Li-Ping</au><au>Cheng, Wei-Hong</au><au>Lee, Wei-Hwa</au><au>Ho, Yuan-Soon</au><au>Chao, Tsu-Yi</au><au>Yeh, Chi-Tai</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1</atitle><jtitle>Experimental cell research</jtitle><addtitle>Exp Cell Res</addtitle><date>2018-09-15</date><risdate>2018</risdate><volume>370</volume><issue>2</issue><spage>519</spage><epage>530</epage><pages>519-530</pages><issn>0014-4827</issn><eissn>1090-2422</eissn><abstract>Failure to eradicate hematologic cancer stem cells (hCSCs) associated with resistance to tyrosine kinase inhibitors such as imatinib mesylate (IM) in chronic myeloid leukemia (CML) patients is a clinical challenge that highlights the need for discovering and developing therapeutic strategies that target and eliminate these hCSCs. Herein, we document the essential role of the interplay between histone deacetylases (HDACs), the polycomb group proteins, pluripotency transcription factors and the cell cycle machinery in the viability, oncogenicity and therapy evasion of IM-resistant CD34+/CD38- CML stem cells (CML-SCs). Using the proteotranscriptomic analyses of wild type (WT), CD34+/CD38+ and CD34+/CD38− K562 or KU812 cells, we showed that CD34+/CD38− SC-enriched cells expressed significantly higher levels of CD44, CD133, SOX2, Nanog, OCT4, and c-Myc mRNA and/or protein, compared to the WT or CD34+/CD38+ cells. This overexpression of stemness factors in the CD34+/CD38− cells positively correlates with enhanced expression of HDACs 1–6, cyclins D1/D3, CDK 2, 4 and 6, while inversely correlating with p18, p21 and p27. Enhanced co-expression of MDR1, survivin, and Bcl-2 proteins, supposedly involved in IM-resistance and CML-SC survival, was detected in both CD34+/CD38− and CD34+/CD38+ cells. Importantly, we demonstrate that in synergism with IM, SAHA reverses the tumor-promoting proteotranscriptomic profile noted above and elicits marked inhibition of the CML-SCs by up-regulating hsa-miR-196a expression. This hsa-miR-196a-mediated SC-limiting effect of SAHA is dose-dependent, low-dosed, cell cycle-modulating and accompanied by leukemic SC apoptosis. Interestingly, this anti-SC therapeutic activity of SAHA in vitro was reproduced in vivo using the NOD-SCID mice models. [Display omitted] •hsa-miR-196a mediates inhibition of CML stem cells.•Potentiate the anticancer effect of Imatinib mesylate by suberanilohydroxamic acid.•Synergism with Imatinib mesylate and suberanilohydroxamic acid reverses the tumor-promoting proteotranscriptomic profile.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>30017934</pmid><doi>10.1016/j.yexcr.2018.07.017</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0014-4827
ispartof Experimental cell research, 2018-09, Vol.370 (2), p.519-530
issn 0014-4827
1090-2422
language eng
recordid cdi_osti_scitechconnect_23082629
source Access via ScienceDirect (Elsevier)
subjects 60 APPLIED LIFE SCIENCES
ALBUMINS
BLOOD SERUM
BORON CHLORIDES
Chemoresistance
Chronic myeloid leukemia
HDAC inhibition
Hematopoietic stem cells
HISTONES
hsa-miR-196a
Imatinib
MESSENGER-RNA
MICE
Myelogenous leukemia
MYELOID LEUKEMIA
PHOSPHOTRANSFERASES
SAHA
STEM CELLS
TYROSINE
title HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T21%3A46%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HDAC%20inhibitor%20suppresses%20proliferation%20and%20tumorigenicity%20of%20drug-resistant%20chronic%20myeloid%20leukemia%20stem%20cells%20through%20regulation%20of%20hsa-miR-196a%20targeting%20BCR/ABL1&rft.jtitle=Experimental%20cell%20research&rft.au=Bamodu,%20Oluwaseun%20Adebayo&rft.date=2018-09-15&rft.volume=370&rft.issue=2&rft.spage=519&rft.epage=530&rft.pages=519-530&rft.issn=0014-4827&rft.eissn=1090-2422&rft_id=info:doi/10.1016/j.yexcr.2018.07.017&rft_dat=%3Cproquest_osti_%3E2071579388%3C/proquest_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2071579388&rft_id=info:pmid/30017934&rft_els_id=S0014482718304403&rfr_iscdi=true